[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pertussiswhooping-cough\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pertussiswhooping-cough":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100551941","the-optimal-timing-of-vaccination-in-pregnancy-100551941",false,"NCT06466629","The Optimal Timing of Vaccination in Pregnancy","The Optimal Timing of Vaccination in Pregnancy: a Multi-dimensional Mechanistic Approach to Measure Immune Responses in Pregnant Women","MATIMMUNE","Inclusion Criteria:\n\n* Ability to provide informed consent.\n* Willing to be vaccinated with a Tdap vaccine during pregnancy.\n* Intend to be available for follow-up visits and phone call access until 6 months postpartum.\n* Influenza and COVID-19 vaccination during pregnancy (as per Belgian recommendations) is allowed.\n\nExclusion Criteria:\n\n* Vaccinated with an aP containing vaccine during the last 5 years\n* Significant mental illness (e.g. schizophrenia, psychosis, major depression)\n* Serious underlying immunological condition (e.g. immunosuppressive disease or therapy, human immunodeficiency virus (HIV) infection…).\n* Systemic treatment with immune suppressive medication, including chronic steroid use of \\> 10 mg prednisone or equivalent.\n* Anything in the opinion of the investigator that would prevent volunteers from completing the study or put the volunteer at risk.\n* Previous severe reaction to any vaccine\n* High risk for serious obstetrical complications.",true,"FEMALE","18 Years",{"count":21,"type":22},96,"ESTIMATED","OBSERVATIONAL","The central aim of this study is to investigate the optimal timing of vaccination in pregnant women. Therefore, pregnant women will be vaccinated against pertussis at different timepoints and blood and breast milk samples will be taken at several timepoints. The main objectives are to assess the impact of timing on humoral and cellular immune responses in pregnant women, on antibody characteristics transferred across the placenta and on transplacental transport efficiency. The impact of maternal pertussis vaccination and timing of maternal pertussis vaccination on breastmilk antibody composition will also be investigated, as well as the impact of vaccination during pregnancy on the mucosal uptake of breastmilk IgA antibodies by the infant respiratory and gastrointestinal tract.",[26],"Pertussis\u002FWhooping Cough","RECRUITING","2024-06-13",{"date":30,"type":31},"2024-06-20","ACTUAL",{"date":33,"type":31},"2021-07-01",{"date":35,"type":22},"2025-04-30",{"name":37,"class":38},"Elke Leuridan, MD, PhD","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":49,"maxAge":19,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":39},"100424500","pediatric-pertussis-in-ambulatory-settings-100424500","NCT04807712","Pediatric Pertussis in Ambulatory Settings","National Surveillance of Pediatric Pertussis in Ambulatory Settings","ACTIVCOQ","Inclusion Criteria:\n\n* All children under 18 years old with a pertussis diagnosis is suspected and a biological exam is requested\n\nExclusion Criteria:\n\n* children without symptoms with a household confirmed case\n* cases for which the pertussis diagnosis was not suspected by the pediatrician","ALL","1 Day",{"count":51,"type":22},898,"Since 2002, Whooping cough surveillance in pediatric private practice has been set up in France. The results of the first years, 2002-2006, have confirmed the effectiveness of the Pertussis whole-cell (Pw) vaccine and in particular the duration of protection of 9\u002F10 years. After evaluating cases in children vaccinated with Pw vaccines, the study aims today to analyze cases in children vaccinated with Pertussis acellular (Pa) vaccines used since 2002\u002F2003 and to assess, on an outpatient basis, the impact of new vaccine recommendations in France (in 2013, introduction of a 2 + 1 schedule - 8 weeks, 4 months and a 11-month recall - and a 6-year recall, and in 2014, update in the recommendations of exams to be prescribed based on the child's age and vaccination status).",[26,54,55],"Children, Only","Ambulatory",[57,58,59],"Pertussis","surveillance","pertussis acellular vaccine","2024-02-07",{"date":62,"type":31},"2024-02-08",{"date":64,"type":31},"2001-05-30",{"date":66,"type":22},"2030-01-01",{"name":68,"class":38},"Association Clinique Thérapeutique Infantile du val de Marne"]